{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:22:51Z","timestamp":1783009371791,"version":"3.54.5"},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A previously healthy 32-year-old male patient was admitted to hospital with malaise, dyspnea, anemia, thrombocytopenia, and leukopenia. Anemia and thrombocytopenia worsened during the third week. Considering the possible need for transfusion, routine ABO and D typing and an antibody detection test were performed. Antibody detection test was positive, necessitating fur ther immunohematologic investigation that revealed an antibody with Kell-related specificity and suppression\/alteration of several high-prevalence Kell blood group system antigens. Autocontrols and direct antiglobulin tests (DATs) were negative in several samples during the disease course. Sequencing of the patient\u2019s\n                    <jats:italic>KEL<\/jats:italic>\n                    and\n                    <jats:italic>XK<\/jats:italic>\n                    genes did not reveal any mutations. Initial tentative diagnosis was myeloid neoplasm based on dyserythropoiesis in the bone marrow smear and no obvious biochemical signs of hemolysis. Azacitidine treatment was initiated, accordingly, but had to be interrupted when the patient\u2019s hemoglobin (Hb) dropped to 4.6 g\/dL in 3 days, and he experienced more severe anemia symptoms (fatigue, nausea, and heart palpitations). Platelet concentrates, and 3 very rare Kell\n                    <jats:sub>null<\/jats:sub>\n                    packed RBC concentrates, imported from abroad, were transfused. However, no increase in Hb was achieved. Platelet autoantibodies were not detected. Suspecting an autoimmune etiology, intravenous immunoglobulin and high-dose glucocorticoids were given. The patient responded to the latter treatment; he felt much better and regained his daily activity, and his Hb value and platelet count normalized on day 45. The steroid dose was tapered during the next 6 months until it was discontinued. His RBCs had normal Kell antigen expression, and the antibody was undetectable on day 105. Therefore, we concluded that an autoimmune etiology was the most plausible cause for the patient\u2019s condition despite a negative DAT. The immunohematologic investigation showed disease-related transient loss and\/or alteration of several Kell system high-prevalence antigens and a Kell-related antibody that appeared to recognize a unique high-prevalence Kell antigen with a not-yet fully defined epitope.\n                  <\/jats:p>","DOI":"10.2478\/immunohematology-2024-021","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T14:22:25Z","timestamp":1735654945000},"page":"153-158","source":"Crossref","is-referenced-by-count":1,"title":["Transient suppression of high-prevalence Kell blood group antigens and concomitant development of a Kell-related antibody that appears to recognize a high-prevalence Kell antigen not previously defined"],"prefix":"10.2478","volume":"40","author":[{"given":"Thomas Larsen","family":"Titze","sequence":"first","affiliation":[{"name":"Department of Immunology and Transfusion Medicine, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norunn","family":"Ulvahaug","sequence":"additional","affiliation":[{"name":"Transfusion Service, Vestfold Hospital , T\u00f8nsberg , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Moksnes","sequence":"additional","affiliation":[{"name":"Cancer and Hematology Center, Vestfold Hospital , T\u00f8nsberg , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna","family":"Skeie","sequence":"additional","affiliation":[{"name":"Department of Immunology and Transfusion Medicine, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja Karamatic","family":"Crew","sequence":"additional","affiliation":[{"name":"International Blood Group Reference Laboratory, NHS Blood and Transplant , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7i\u011fdem Akal\u0131n","family":"Akk\u00f6k","sequence":"additional","affiliation":[{"name":"Department of Immunology and Transfusion Medicine, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Thornton","sequence":"additional","affiliation":[{"name":"International Blood Group Reference Laboratory, NHS Blood and Transplant , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"2026070214584043720_j_immunohematology-2024-021_ref_001","unstructured":"International Society of Blood Transfusion. 006 KEL Alleles. Available from isbtweb.org). Accessed 10 May 2024."},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_002","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937\u201351. doi:10.1182\/blood-2009-03-209262.","DOI":"10.1182\/blood-2009-03-209262"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_003","doi-asserted-by":"crossref","unstructured":"Pelc-K\u0142opotowska M, P\u0142oski R, Szcza\u0142uba K, et al. A novel KEL c.1414-1G>T allele in a Polish patient with anti-Ku antibody. Transfusion 2022;62:E43\u20134. doi:10.1111\/trf.17040.","DOI":"10.1111\/trf.17040"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_004","doi-asserted-by":"crossref","unstructured":"Lydaki E, Nikoloudi I, Kaminopetros P, et al. Serial blood donations for intrauterine transfusions of severe hemolytic disease of the newborn with the use of recombinant erythropoietin in a pregnant woman alloimmunized with anti-Ku. Transfusion 2005;45:1791\u20135. doi:10.1111\/j.1537-2995.2005.00604.x.","DOI":"10.1111\/j.1537-2995.2005.00604.x"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_005","doi-asserted-by":"crossref","unstructured":"Gustavsen A, Njerve IU, Sitras V, Haugen G, T\u00f8ll\u00f8fsrud PA, Akk\u00f6k \u00c7A. A young woman with a transfusion-related pregnancy complication. Tidsskr Nor Laegeforen 2020;140. doi:10.4045\/tidsskr.19.0117.","DOI":"10.4045\/tidsskr.19.0117"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_006","doi-asserted-by":"crossref","unstructured":"Seyfried H, G\u00f3rska B, Maj S, Sylwestrowicz T, Giles CM, Goldsmith KL . Apparent depression of antigens of the Kell blood group system associated with autoimmune acquired haemolytic anaemia. Vox Sang 1972;23:528\u201336. doi:10.1111\/j.1423-0410.1972.tb03846.x.","DOI":"10.1111\/j.1423-0410.1972.tb03846.x"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_007","doi-asserted-by":"crossref","unstructured":"Beck ML, Marsh WL, Pierce SR, DiNapoli J, Oyen R, Nichols ME. Auto anti-Kpb associated with weakened antigenicity in the Kell blood group system: a second example. Transfusion 1979;19:197\u2013202. doi:10.1046\/j.1537-2995.1979.19279160294.x.","DOI":"10.1046\/j.1537-2995.1979.19279160294.x"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_008","unstructured":"Alvarez A, Rives S, Montoto S, Sanz C, Pereira A. Relative sensitivity of direct antiglobulin test, antibody\u2019s elution and flow cytometry in the serologic diagnosis of immune hemolytic transfusion reactions. Haematologica 2000;85:186\u20138."},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_009","unstructured":"Geoff D. Human blood groups. 3rd ed. Oxford, UK: Wiley-Blackwell; 2013."},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_010","doi-asserted-by":"crossref","unstructured":"Wagner T, Lanzer G, Geissler K. Kell expression on myeloid progenitor cells. Leuk Lymphoma 2002;43:479\u201385. doi:10.1080\/10428190290011949.","DOI":"10.1080\/10428190290011949"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_011","doi-asserted-by":"crossref","unstructured":"Johnson ST. JMH blood group system: a review. Immunohematology 2014;30:18\u201323. doi:10.21307\/immunohematology-2019-094.","DOI":"10.21307\/immunohematology-2019-094"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_012","doi-asserted-by":"crossref","unstructured":"Shafiq M, Karim F. Red cell antigen loss in a patient with chronic myeloid leukemia: a case of ABO discrepancy. Transfus Apher Sci 2015;52:103\u20134. doi:10.1016\/j.transci.2014.11.004.","DOI":"10.1016\/j.transci.2014.11.004"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_013","doi-asserted-by":"crossref","unstructured":"Nambiar RK, Narayanan G, Prakash NP, Vijayalakshmi K. Blood group change in acute myeloid leukemia. Proc (Bayl Univ Med Cent) 2017;30:74\u20135. doi:10.1080\/08998280.2017.11929536.","DOI":"10.1080\/08998280.2017.11929536"},{"key":"2026070214584043720_j_immunohematology-2024-021_ref_014","doi-asserted-by":"crossref","unstructured":"Judd WJ, Annesley TM. The acquired-B phenomenon. Transfus Med Rev 1996;10):111\u20137. doi:10.1016\/s0887-7963(96)80087-3.","DOI":"10.1016\/S0887-7963(96)80087-3"}],"container-title":["Immunohematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/immunohematology-2024-021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:57:34Z","timestamp":1783007854000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/immunohematology-2024-021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,31]]},"published-print":{"date-parts":[[2024,12,1]]}},"alternative-id":["10.2478\/immunohematology-2024-021"],"URL":"https:\/\/doi.org\/10.2478\/immunohematology-2024-021","relation":{},"ISSN":["1930-3955"],"issn-type":[{"value":"1930-3955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}